Parkinson’s Disease (PD) Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Systemic Lupus Erythematosus ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsNon-alcoholic Steatohepatitis (NASH) ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurodegenerative Disease Mouse Models
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Parkinson's disease (PD) is a chronic, neurodegenerative disorder that mostly affects the motor system. The clinical andbehavioral characteristics of Parkinson's disease include tremor, tonicity, bradykinesia, and gait abnormalities, whereas the pathology is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the formation of Lewy bodies (LB) in the cytoplasm. Many risk factors, such as α-synuclein aggregation in LB and mitochondrial dysfunction, have been proposed in relation to complex theories about possible PD mechanisms.

GemPharmatech has developed two PD models that can be used for screening, safety evaluation, and efficacy evaluation of therapeutics.

Strain No.
 Strain Name Strain Type Description
T054329 B6-hSNCA-A53T Transgenic Targeting the A53T mutation Loci of SNCA, GemPharmatech has developed the B6- hSNCA A53T model, which can be applied in the screening and safety evaluation of Parkinson's disease (PD) therapies and the research of PD pathophysiology.
T053276 B6-Tfam-flox/Slc6a3-Cre CKO GemPharmatech has developed a Tfam-CKO mouse model that demonstrates decreased TH+ neurons and impaired exercise capacity in the substantia nigra region from 2 to 3 months of age, which is comparable with the clinical phenotype of Parkinson's disease. This model can be used for the screening, safety evaluation, and pathogenesis of PD drugs.